Abstract：
OBJECTIVE: Peripheral neuropathy (PN), as an adverse reaction attributed to statin drugs, as well as the beneficial neuroprotective properties of statins, have been widely reported and discussed in the literature. The aim of this study was to systematically review original publications that investigated the association of statin use and PN in diabetic and non-diabetic models, whether determined as a result of laboratory experimentation, or in a clinical setting.
RESULTS: A comprehensive search of the databases Google Scholar, PubMed/MEDLINE and Scopus was conducted. Sixty-six articles, which evaluated the link between statins and PN in either a clinical or in-vivo/in-vitro condition were included. Statin treatment in neuropathy-induced animal models demonstrates favourable neurological effects in both the morphological and functional aspects of neurons. However, an extended duration of statin treatment is minimally associated with the development of non-diabetic idiopathic neuropathy. Importantly, statins have the potential to regress diabetic PN through anti-inflammatory, anti-oxidant and immunomodulatory properties.
CONCLUSIONS: When interpreting the results from studies that deal with the relationship between statins and PN, it is important to determine the mechanism(s) underlying the development of any potential neuropathies (in the presence or absence of diabetes), the type of model used (human or animal) and the duration of statin treatment.
RESULTS: A comprehensive search of the databases Google Scholar, PubMed/MEDLINE and Scopus was conducted. Sixty-six articles, which evaluated the link between statins and PN in either a clinical or in-vivo/in-vitro condition were included. Statin treatment in neuropathy-induced animal models demonstrates favourable neurological effects in both the morphological and functional aspects of neurons. However, an extended duration of statin treatment is minimally associated with the development of non-diabetic idiopathic neuropathy. Importantly, statins have the potential to regress diabetic PN through anti-inflammatory, anti-oxidant and immunomodulatory properties.
CONCLUSIONS: When interpreting the results from studies that deal with the relationship between statins and PN, it is important to determine the mechanism(s) underlying the development of any potential neuropathies (in the presence or absence of diabetes), the type of model used (human or animal) and the duration of statin treatment.
摘要：
目标：周围神经病变（PN），作为归因于他汀类药物的不良反应，以及他汀类药物有益的神经保护特性，在文献中得到了广泛的报道和讨论。这项研究的目的是系统地回顾研究糖尿病和非糖尿病模型中他汀类药物使用与PN的关系的原始出版物。是否作为实验室实验的结果确定，或在临床环境中。
结果：对GoogleScholar数据库的全面搜索，进行了PubMed/MEDLINE和Scopus。六十六篇文章，包括在临床或体内/体外条件下评估他汀类药物与PN之间的联系。神经病诱导的动物模型中的他汀类药物治疗在神经元的形态和功能方面都显示出有利的神经作用。然而,他汀类药物治疗持续时间的延长与非糖尿病性特发性神经病的发展最小相关.重要的是,他汀类药物有可能通过抗炎，抗氧化和免疫调节特性。
结论：当解释来自处理他汀类药物与PN之间关系的研究的结果时，重要的是要确定潜在的神经病（在存在或不存在糖尿病的情况下）发展的机制，使用的模型类型（人或动物）和他汀类药物治疗的持续时间。
结果：对GoogleScholar数据库的全面搜索，
结论：当解释来自处理他汀类药物与PN之间关系的研究的结果时，
